eBOOKS BY CATEGORY
Your Account
Therapeutic Targets
Modulation, Inhibition, and Activation
Price
Quantity
£125.00
(To see other currencies, click on price)
ePub
Add to basket  

MORE ABOUT THIS BOOK

Main description:

The Latest Applications For Cellmechanism Research in Drug Discovery


Designed to connect research on cell mechanisms with the drug discovery process, Therapeutic Targets: Modulation, Inhibition, and Activation introduces readers to a range of new concepts and novel approaches to drug screening and therapeutic drug targeting to help inform future avenues of drug research. Highly topical, this accessible edited volume features chapters contributed by respected experts from around the globe.


The book helps postgraduate students and professional scientists working in academia and industry understand the molecular mechanisms of pharmacology, current pharmacological knowledge, and future perspectives in drug discovery, focusing on important biochemical protein targets and drug targeting strategies for specific diseases. Examining the pharmacology of therapeutically undefined targets and their potential applications, it includes chapters on traditional therapeutic targets, including enzymes (phosphodiesterases and proteases), ion channels, and G protein–coupled receptors, as well as more recently identified avenues of exploration, such as lipids, nuclear receptors, gene promoters, and more.


Since different diseases require different targeting techniques, the book also includes dedicated chapters on strategies for investigating Alzheimer′s, diabetes, pain, and inflammation treatments. Concluding with a cross–sectional look at new approaches in drug screening, Therapeutic Targets is an invaluable resource for understanding where the next generation of drugs are likely to emerge.


Back cover:

The Latest Applications For Cellmechanism Research in Drug Discovery


Designed to connect research on cell mechanisms with the drug discovery process, Therapeutic Targets: Modulation, Inhibition, and Activation introduces readers to a range of new concepts and novel approaches to drug screening and therapeutic drug targeting to help inform future avenues of drug research. Highly topical, this accessible edited volume features chapters contributed by respected experts from around the globe.


The book helps postgraduate students and professional scientists working in academia and industry understand the molecular mechanisms of pharmacology, current pharmacological knowledge, and future perspectives in drug discovery, focusing on important biochemical protein targets and drug targeting strategies for specific diseases. Examining the pharmacology of therapeutically undefined targets and their potential applications, it includes chapters on traditional therapeutic targets, including enzymes (phosphodiesterases and proteases), ion channels, and G protein–coupled receptors, as well as more recently identified avenues of exploration, such as lipids, nuclear receptors, gene promoters, and more.


Since different diseases require different targeting techniques, the book also includes dedicated chapters on strategies for investigating Alzheimer′s, diabetes, pain, and inflammation treatments. Concluding with a cross–sectional look at new approaches in drug screening, Therapeutic Targets is an invaluable resource for understanding where the next generation of drugs are likely to emerge.


Contents:

Preface vii


Contributors ix


1. cAMP–Specific Phosphodiesterases: Modulation, Inhibition, andActivation 1
R. T. Cameron and George S. Baillie


2. Protease–Activated Receptor 2 37
Qihai Gu and Lu–Yuan Lee


3. Voltage–Gated Sodium Channels as Therapeutic Targets 63
Joshua S. Wingerd, Irina Vetter, and Richard J. Lewis


4. Multitarget Drugs for Stabilization of Calcium Cycling andNeuroprotection in Neurodegenerative Diseases and Stroke 123
Antonio M. G. de Diego, Silvia Lorrio, Jesús M.Hernández–Guijo, Luis Gandía, and Antonio G.García


5. Oligomerization of G–Protein–Coupled Receptors 201
Juan F. López–Giménez and JavierGonzález–Maeso


6. Sigma 1 Receptor Chaperone: Pharmacology and TherapeuticPerspectives 225
Daniel Zamanillo, Enrique Portillo–Salido, José MiguelVela, and Luz Romero


7. Lipids as New Targets 279
Eduardo Domúnguez


8. Knowledge Base for Nuclear Receptor Drug Discovery 309
Albert A. Antolín and Jordi Mestres


9. Gene Promoters and Transcription Control Regions asTherapeutic Targets 327
Antonio Zorzano, David Sebastian, Jana Sánchez–Wandelmer,Laia Miret, and Fernando Albericio


10. Roles of Glucagon–Like Peptide and Glucose–DependentInsolinotropic Polypeptide Hormones in Brain Function andNeurodegeneration 351
Christian Hölscher


11. Exocytotic Machinery as a Target for the Development of NewDrugs for Schizophrenia 375
María Jose Guerrero, Itsaso Hormaeche, MaríaUribarri, Julie Masse, and José María Palacios


12. Targeting Epigenetic Abnormalities in the Brain 409
Erin Y. Sterner, Lisa E. Kalynchuk, and Hector J.Caruncho


13. Rodent Models as Tools for Discovering Novel TherapeuticTargets in the Brain: The Case of Epilepsy 427
Justin J. Botterill, Axel J. Guskjolen, Lisa E. Kalynchuk, andHector J. Caruncho


14. New Approaches Applied to Drug Screening 455
José Brea and María Isabel Loza


Index 477


PRODUCT DETAILS

ISBN-13: 9781118185520
Publisher: John Wiley & Sons Ltd (Wiley–Blackwell)
Publication date: June, 2012
Pages: 494
Dimensions: 160.00 x 241.00 x 30.79

Subcategories: Diseases and Disorders, Pharmacology

MEET THE AUTHOR

Luis M. Botana was Director of the Department of Pharmacology at the University of Santiago de Compostela (USC), Director of the European Union Reference Laboratory for Marine Biotoxins, and scientific advisor to the drug company LCIFGA. The author of 200 papers and 15 patents, Dr. Botana is the editor of several other books, including Phycotoxins: Chemistry and Biochemistry, published by Wiley (2007).


Mabel Loza is Professor of Pharmacology at the University of Santiago de Compostela (USC). She created the USEF Drug Screening Platform, with more than ten years of experience in public and private mixed early drug discovery programs.